Pharmacy Times April 9, 2025
Luke Halpern, Assistant Editor, Nilufer Ertekin-Taner, MD, PhD

Nilufer Ertekin-Taner contrasts current one-size-fits-all Alzheimer disease treatments with the promise of precision medicine and emphasizes the vital role of collaborative, multidisciplinary care.

In an interview with Pharmacy Times®, Nilufer Ertekin-Taner, MD, PhD, FAAN, a member of the department of neurology at Mayo Clinic, discusses her plenary session “A Roadmap to Precision Medicine in Neurodegenerative Diseases,” which she presented at the American Academy of Neurology 2025 Annual Meeting, taking place from April 5 to April 9 in San Diego, California.

Ertekin-Taner explains that current Alzheimer disease (AD) treatments largely focus on symptomatic relief and fail to address the underlying biological diversity among patients. She envisions a future where patients are biologically classified by disease subtype and stage, with therapies tailored...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: Interview / Q&A, Pharma / Biotech, Precision Medicine, Trends
Related Articles:
JPM 2026: Genoa Ventures’ Jenny Rooke on Next-Gen Clinical Assessment Tools
From Early Detection to Targeted Therapy: How AI is Reframing Precision Medicine
How Precision Medicine and AI are Evolving: An MD Anderson Perspective
Bringing Precision Medicine Into the Home
Inside the Virtual Cell: New Depths for Precision Medicine

Share Article